Literature DB >> 7993663

Anabolic effect of human growth hormone: management of inherited disorders of catabolic pathways.

D Marsden1, B A Barshop, S Capistrano-Estrada, M Rice, C Prodanos, D Sartoris, J Wolff, K L Jones, S Spector, W L Nyhan.   

Abstract

The effects of growth hormone treatment and dietary alanine supplementation, individually and in combination, were studied in five patients with organic acidemias. Three patients had propionic acidemia, one had 3-hydroxyisobutyric acidemia, and one had a defect in isoleucine metabolism. Two patients with propionic acidemia had decreased growth hormone secretion in response to provocative stimuli (intravenous L-arginine and oral levodopa or clonidine); the remaining subjects had sufficient growth hormone secretion. Three of four subjects in whom IGF1 was measured showed subnormal concentrations at baseline (including two with normal growth hormone secretory responses). All patients showed an increase in linear growth with growth hormone. In the four patients studied, all had a significant increase in nitrogen retention over baseline with alanine or growth hormone alone, or with the combination of growth hormone and alanine, with a much greater effect of growth hormone. Lean body mass and body fat composition tended to become normal with treatment. Protein tolerance increased, and when the patients' dietary protein intakes were increased between 20 and 60% they maintained positive nitrogen balance, without a significant increase in metabolite excretion. One patient with propionic acidemia expired during the time of the study, following a course of recurrent pancreatitis and an episode of acute basal ganglia infarction. All of the other subjects showed clinical improvement (decreased incidence of ketoacidotic episodes and decreased frequency of hospital admission and school absence) during treatment, and even the patient who expired remained metabolically stable up to and through the terminal event. We conclude that growth hormone may be of value in the management of patients with organic acidemia.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7993663     DOI: 10.1006/bmmb.1994.1047

Source DB:  PubMed          Journal:  Biochem Med Metab Biol        ISSN: 0885-4505


  9 in total

1.  Methylmalonic and propionic acidurias: management without or with a few supplements of specific amino acid mixture.

Authors:  G Touati; V Valayannopoulos; K Mention; P de Lonlay; P Jouvet; E Depondt; M Assoun; J C Souberbielle; D Rabier; H Ogier de Baulny; J-M Saudubray
Journal:  J Inherit Metab Dis       Date:  2006 Apr-Jun       Impact factor: 4.982

2.  Growth hormone therapy is safe and effective in patients with lysinuric protein intolerance.

Authors:  Harri Niinikoski; Risto Lapatto; Matti Nuutinen; Laura Tanner; Olli Simell; Kirsti Näntö-Salonen
Journal:  JIMD Rep       Date:  2011-06-22

3.  Alanine prevents the decrease of Na+,K+-ATPase activity in experimental phenylketonuria.

Authors:  A T Wyse; M E Noriler; L F Borges; P J Floriano; C G Silva; M Wajner; C M Wannmacher
Journal:  Metab Brain Dis       Date:  1999-06       Impact factor: 3.584

4.  Inhibition of the mitochondrial respiratory chain by alanine in rat cerebral cortex.

Authors:  Virginia C Rech; Luciane R Feksa; Carlos S Dutra-Filho; Angela T S Wyse; Moacir Wajner; Clovis M D Wannmacher
Journal:  Metab Brain Dis       Date:  2002-09       Impact factor: 3.584

5.  Alanine prevents the inhibition of pyruvate kinase activity caused by tryptophan in cerebral cortex of rats.

Authors:  Luciane Rosa Feksa; Andrea Renata Cornelio; Carmem Regla Vargas; Angela Terezinha de Souza Wyse; Carlos Severo Dutra-Filho; Moacir Wajner; Clovis Milton Duval Wannmacher
Journal:  Metab Brain Dis       Date:  2003-06       Impact factor: 3.584

Review 6.  Emergency management of inherited metabolic diseases.

Authors:  V Prietsch; M Lindner; J Zschocke; W L Nyhan; G F Hoffmann
Journal:  J Inherit Metab Dis       Date:  2002-11       Impact factor: 4.982

7.  Alanine prevents the reduction of pyruvate kinase activity in brain cortex of rats subjected to chemically induced hyperphenylalaninemia.

Authors:  Luciane Rosa Feksa; Andrea Renata Cornelio; Virginia Cielo Rech; Carlos Severo Dutra-Filho; Angela Terezinha Souza Wyse; Moacir Wajner; Clóvis Milton Duval Wannmacher
Journal:  Neurochem Res       Date:  2002-09       Impact factor: 3.996

8.  Growth hormone as a rescue treatment in maple syrup urine disease with lessons from pediatric burn literature, case report and brief literature review.

Authors:  Brooke E Kimbrell; Faith Hicks; Cortney B Foster; Omayma A Kishk; Sara A Quinteros-Fernandez; Maria Eleni Nikita; Carol L Greene
Journal:  Mol Genet Metab Rep       Date:  2020-12-13

Review 9.  Proposed guidelines for the diagnosis and management of methylmalonic and propionic acidemia.

Authors:  Matthias R Baumgartner; Friederike Hörster; Carlo Dionisi-Vici; Goknur Haliloglu; Daniela Karall; Kimberly A Chapman; Martina Huemer; Michel Hochuli; Murielle Assoun; Diana Ballhausen; Alberto Burlina; Brian Fowler; Sarah C Grünert; Stephanie Grünewald; Tomas Honzik; Begoña Merinero; Celia Pérez-Cerdá; Sabine Scholl-Bürgi; Flemming Skovby; Frits Wijburg; Anita MacDonald; Diego Martinelli; Jörn Oliver Sass; Vassili Valayannopoulos; Anupam Chakrapani
Journal:  Orphanet J Rare Dis       Date:  2014-09-02       Impact factor: 4.123

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.